WHILE there is a vast literature on the effects of oestrogens and androgens on tumours, only a few reports have appeared in the last two or three years on clinical experience with progestins in human cancer. Kelley and Baker (1961 Loraine and Strong (1960) who studied the effects of 19-norethistosterone oenanthate, an early non-marketed German product. Only one patient in their series showed a favourable response. The indications for the use of a hormone which appears to exert its biological activity through an influence on connective tissue structures need hardly be stressed. The availability of a long acting progesterone preparation in the form of Primolut Depot (Delalutin in U.S.A.) prompted, in 1957, the start of a study of its growthrestraining effects in a small series of cases of advanced malignant tumours of breast, ovary and uterus. The findings and the discussion of the rationale of treatment are the subject of this preliminary note.
Depot (Delalutin in U.S.A.) prompted, in 1957, the start of a study of its growthrestraining effects in a small series of cases of advanced malignant tumours of breast, ovary and uterus. The findings and the discussion of the rationale of treatment are the subject of this preliminary note.
THE HORMONE AND CLINICAL MATERIAL
It is generally accepted that the pharmacological properties of synthetic progesterone are comparable to natural corpus luteum hormone. The disadvantage of its low solubility, hence underdosage in clinical use, has been overcome by the development of hydroxyprogesterone capronate by hydrolysis from progesterone. Concentrated in Primolut Depot -up to 250 mg. in 1 ml. of oily solution it has an activity lasting over one week. Other derivatives such as 17a-alkyl-19-nor-testosterone (Junkmann, 1954) with the trade name of Primolut N and 17ac-ethinyl-17-hydroxy-5(10)-oestren-3-one, enhanced by etbinyloestradiol 3-methyl ether, marketed as Enavid, have the advantage of a marked oral activity. The capronate form has a progestational action, prompt and twice as marked and 2 to 4 times more prolonged than free progesterone. Kistner (1958) claims that Primolut Depot in comparison with free 17a-hydroxyprogesterone is 30 times more effective and 5 times more prolonged in its action. It is claimed to have a weak anti-gonadotrophic action and, similar to progesterone, little effect on the menstrual cycle. It has shown no androgenic effects in animal experiments (Suchowsky and Junkmann, 1961) . Twenty-seven patients with tumours of the breast, ovary and uterus, in very advanced stages, in which other methods of treatment-surgery, radiotherapy, oestrogens or androgens or chemotherapy have failed or have lost their effectiveness have been treated.
Of the 27 cases here reviewed there were 9 cases of carcinoma of breast, 10 cases of carcinoma of the ovary and 8 cases of malignant tumours of the uterus (2 cervical cases). The dosage was 250 mg. once a week; in 2 cases the compound was given in tablet form-Norethisterone-30 mg. daily.
The Primolut Depot, 1 7x-hydroxyprogesterone capronate, has not in this series caused any untoward side effects. There were no reactions at the site of the injections.
Fifteen patients have shown subjective improvement, with increased appetite and a sense of well being. In some, objective signs of improvement were noted. Table I shows the response to progesterone treatment assessed on the basis of clinical and radiological findings, and the statements of the patients' own general practitioners, and patients themselves concerning their objective and subjective improvement. Details of age, histology, previous surgery, radiotherapy, hormonetherapy or chemotherapy, the dosage of progesterone administered and response are set out in Tables II, III and IV. In the series of 9 cases of advanced carcinoma of breast, the outstanding success of treatment with progesterone was that of Case 2 with skin recurrences in the pectoral region and abdominal metastases, and subsequently a tumour mass in the opposite breast which remains quiescent. This patient is doing well and has been on progesterone for over 31 years, with a total dose of nearly 60,000 mg. Not only were there no untoward side effects but the patient's well-being has been maintained throughout. The suggestion made to the patient to discontinue progesterone for a while in order to enable an assessment of its real subjective value met with a flat refusal because of the experience gained from the occasional omission or delay of the weekly dose which had brought a deterioration in the patient's general condition, unduly easy fatigue and a sensation which can only be described as that of deprivation. Similar statements were volunteered by 2 other patients. One with leiomyosarcoma of the uterus (Case 20) who has benefited both subjectively and objectively (reduction in size of palpable mass in pelvis, abolition of pain and improvement of general condition), and a patient with an ovarian tumour (Case 13) with ascites and bilateral pleural effusions, in whom progesterone was thought to be responsible for the drying up of the pleural effusion altogether until the time of death, and had at first also prolonged considerably the period between paracenteses. The latter, however, had to be subsequently resumed. In this patient clinically the undoubted effect was short lived (3 months), but it must be added that this particular patient had received also, at the beginning of the series of progesterone injections, nitrogen mustard (Thiotepa, 5 x 15 mg.).
In the other cases in whom the results were noted as " fair improvement" there was no doubt of the slight amelioration of the patients' condition. It must be stressed, however, that the dosage has been on the low side, and it seems that at least initially a dose of 500 mg. weekly is indicated.
The drying up of the ascites and pleural effusions after progesterone treatment was the outstanding feature in Case 13, and of ascites in Cases 10 and 17.
Similar results were observed by Kelley and Baker (1961) who used various preparations of progestational agents including aqueous suspension of progesterone in oil and 17 ac-hydroxyprogesterone capronate in weekly doses ranging from 150 to 1000 mg. Six out of 21 patients with endometrial carcinoma benefited (5 showed regression of pulmonary metastases), the remissions lasting from 9 months to 4-years. Three of these died; in one the disease progressed and two enjoyed a remission on continual progesterone therapy.
Of the few results of treatment with free progesterone used, before synthetic preparations allowing the administration of high dosages were available, the following are worth recording. While Hertz, Cromer, Young and Westfall (1951) noticed visible and palpable regression of carcinoma of cervix uteri in 11 out of 17 patients treated with free progesterone, Gordon, Horwitt Segaloff, Murison and Schlosser (1952) Volk and Lewin, 1961 ) treated with synthetic progesterone was that of a male patient whose secondary bone deposits showed recalcification after treatment with 17 a-hydroxyprogesterone--250 mg. daily.
DISCUSSION
No impressive results could be expected in the group of patients here described, and the response noted as fair was that which is encountered in a proportion of cases treated with oestrogens or androgens. When, however, allowance is made for the inadequate amounts of progesterone actually taken because of the terminal stage at which the treatment was instituted and the interesting observations of reduction in size of tumour, drying up of effusions and subjective improvements produced, the value of progestins in treatment of some tumours appears to warrant a further study of their effects in malignant disease. As a sound approach to hormone therapy must be based not only on research in the endocrinological and clinical fields, but have a background of ideas concerning the mechanism of action of a new compound, i.e. a rationale for its application, a discussion of the latter seems desirable. For this reason the effects of progestins on the humoral and tissue levels will be briefly discussed.
The mechanism of action of progestins is not clear. It is worth mentioning that Jenkins (1961) , who has described the effects of progesterone in cyclical ascites, is of the opinion that the electrolyte excretion plays an important role in this respect, progesterone acting as an aldosterone antagonist. This is probably borne out by the effects on ascites and pleural effusion in the cases of ovarian tumour.
It is not yet clear whether intermediate metabolites come into action, and it
is not certain whether all progestins have an inhibitory effect on gonadotrophin secretion. It is assumed that Primolut Depot has very little direct effect on the pituitary. Other progesterones may have different mechanisms of action. The group of Edinburgh workers (Douglas, Loraine and Strong, 1960) found that 19-norethistosterone oenanthate in 12 cases of mammary carcinoma had little effect, only one case showing improvement. However, there are differences in the metabolism and physiological effects of the two progesterones, and this aspect awaits further investigation. In Table V are set out data concerning the metabolism of a few progestins and their side effects. Titres of follicle-stimulating hormone in one patient measured by Kelley and Baker (1961) showed no suppression of the pituitary during treatment. Sherman and Woolf (1959) noted a drop in elevated levels of luteinizing hormone in 4 patients with carcinoma of the endometrium who received 1 7-hydroxyprogesterone capronate for six weeks. As these authors do not state whether there has been tumour regression in their cases the question of an effect via the pituitary gland remains an open one. Sherman and Woolf (1959) suggest that in cases of endometrial carcinoma an increased LH production exercises an influence on an abnormally high complement of hilar (Leydig or theca) cells which are kept in check during reproductive years by progesterone derived from successive corpora lutea. After menopause this restraint is no longer available and the ensuing excessive oestrogen production is followed by an endocrinal pattern leading through a phase of cystic adenomatous hyperplasia and anaplasia to carcinoma. By introducing into the body of a hormone which may act by the proper feed-back action on the pituitary the endocrine pattern, as suggested by these authors, might be interfered with either prophylactically or as a curative measure in established neoplasia. Kistner (1958) who studied the effect of 17ax-hydroxyprogesterone in endometriosis suggests that the esterified steroid is transported intact to the tissues where it exerts its biologic activity, and there is slowly metabolized as it induces its action. Brown, Fotherby and Loraine (1960) in their study of the effects of 17x-ethinyl-19-norethisterone on the urinary excretion of oestrogens, pregnanendiol and gonadotrophins during the menstrual cycle postulate that norethisterone exerts its effect by a direct action on the ovary rather than through the pituitary. It is generally assumed that oestrogens exert their influence on malignant cells directly, and little attention has been paid to histological changes produced in intercellular structures deeply affected both structurally and functionally by steroids. The importance of these changes cannot be over-rated.
Facts regarding histological changes by endocrine glands on connective tissue are very fragmentary. Important clues concerning the anatomical and functional state of tissues in hormone dependent organs (uterus, breast) come from observations of the physiological changes which these organs undergo during lactation, the menstrual cycle and in the menopause. The oedema of the stroma in the proliferative and secretory phases of the menstrual cycle, followed by the destruction and shedding of this structure with the menstruating endometrium (Zuckerman, 1949) is most interesting in this context. Muller (1951) found that the effects of subcutaneously injected oestrogen on loose connective tissue in rats were different from those on the dense connective tissue. In the former oestrogen induced a rejuvenation process, as shown by the development of a fine reticular network and an increase of ground substance, while in the dense connective tissue it induced a maturation process with an increase in the denseness and number of collagen bundles. Pliske (1953) found in guinea-pigs marked hypertrophy of epidermal cells and swelling of the collagen fibre bundles producing a nearly homogeneous condition in the tissue with interfibrous vacuoles containing degenerating fibroblast nuclei appearing regularly between the fibre bundles. Jolles, Greening, Dun and Timms (1956) found in a series of rabbits' ears treated with local estrogen applications that the most marked changes were in the epidermis and the collagen of the dermis.
In the epidermis, contrary to the findings of Pliske (1953) , no decrease in the number of layers of epidermal cells was noted; an increase in these was found constantly in the experimental and control ears in the latter due probably to oestrogen released into the circulation. In the dermis, swelling of the collagen fibres and an appearance of " homogeneity " of the dermis appeared to be characteristic. Examination of fibres by means of electron microscopy did not reveal changes in the amount of coating material noted in experiments in which a reversible " maturation " of collagen (characterized by a decrease due to dispersal or clearing of coating material of collagen fibrils) was induced by mechanical means such as stretching.
The " antifibromatogenic " (Lipschuitz, 1950) effect of progesterone has been known for a long time, but the main indications for its use in the gynaecological field have been endometriosis, dysmenorrhoea and threatened habitual abortion. The effects of progesterone on experimental tumour growth is that of acceleration on the one hand (Ehrlich tumours in rats)-latency period halved, followed by rapid growth, while on the other hand if the rats were pretreated with progesterone their survival was prolonged (Rio, 1957) .
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A compound such as synthetic progesterone which has the effect of a " decidual transformation" of the endometrial stroma may play an important role in the management of tumours in hormone-dependent organs. Changes in tumour stroma and mesenchymal tissues in general may affect not only the rate of spread but induce a regression of tumour when the prevailing conditions are rendered unfavourable. The physio-chemical state of intercellular tissue components, the degree of their imbibition, the state of the connective tissue ground substance in tumour and tumour bed have to be considered. It is relevant to recall the fact that oedema unfavourably influences tumour response in radiotherapy. Changes in tumour stroma and tumour bed brought about by ionizing radiation represent a relevant part of the beneficial reaction leading to the destruction of tumour and repair (Jolles and Koller, 1950; Jolles, 1953) . Untimely and excessive fibrosis in irradiated tumours may on occasion jeopardize the outcome of treatment. Thus, a hormone which causes the disappearance of fibrosis in endometriosis could be used with advantage as a coadjuvant of other forms of therapy.
The key position of progestins in steroid metabolism renders this hormone interesting when one considers the advisability of an attack on many fronts at an early stage of malignant disease. The clinical observations made in the series of cases described are encouraging enough and it is hoped that further experience in less advanced stages of malignant disease will throw more light on this and related problems.
SUMMARY
Twenty-seven patients with advanced malignant tumours of the breast (9), ovary (10) and uterus (8) were treated with a progesterone steroid 17a-hydroxyprogesterone capronate. A good response was noted in 10 cases. A rationale of treatment and the possible mechanisms of action of this hormone are discussed.
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